A phase I study of SS1P given as a bolus i.v. infusion to 2 patients with mesothelin-expressing pancreatic cancers was published in 2007 showing safety and feasibility but, unfortunately, no clinical response [17]. Here, MSLN is linked to pancreatic neoplasm.